The S&P has made an all-time high for nine-straight quarters, but CNBC's Jim Cramer says there's reason to think it's sustainable.» Read More
NEW YORK, April 14- After years of responding to shareholder calls for stock buybacks and dividends, major American companies are hearing a different demand from investors: buy growth.
SAN FRANCISCO/ NEW YORK, April 10- Carl Icahn backed off calls for eBay Inc to spin out its fast-growing PayPal payments unit on Thursday, after the billionaire investor failed to drum up support from the e-commerce company's major shareholders. Icahn withdrew his two nominees to eBay's board ahead of the company's annual meeting in May.
NEW YORK— Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million. The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18. The stock rose as much as $1.24, or 7.8 percent, in morning trading but later declined 25 cents to $15.75.
The company has a deal with Forest Laboratories for co-creation of a dementia drug, which is pending FDA approval. Ally Financial Inc.- The finance company's offering could make taxpayers whole for a $17.2 billion government bailout during the financial crisis. Ally, known as GMAC Inc. at the time of its bailout, had been the auto lending arm for General Motors.
*Morgan Stanley tops global rankings. LONDON, March 28- A string of large transactions drove the value of global mergers and acquisitions activity up by 54 percent in the first quarter compared to the same period last year, reflecting greater deal-making confidence among chief executives.
MUMBAI, March 6- Sun Pharmaceutical Industries Ltd, India's biggest drugmaker by market value, is looking for partnerships or acquisitions to enter Japan, an especially lucrative market for manufacturers of low-cost drugs, a senior executive said.
Feb 27- Valeant Pharmaceuticals International Inc sees close to 50 opportunities for mergers or acquisitions, its chief executive said on Thursday, as it aims to become one of the world's five biggest pharmaceutical companies.
NEW YORK, Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal payments business.
Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division.
Feb 24- Billionaire investor Carl Icahn accused eBay Inc Chief Executive John Donahoe of failing to spot- or ignoring- conflicts of interest on the company's board and called again for the spinoff of its fast-growing PayPal division. Marc Andreessen and Scott Cook, both long-term eBay board members, bore the brunt of Icahn's conflict allegations.
Despite his mild concern, influential investor Dennis Gartman says it's still a bull market for stocks.
Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.
Stocks mostly rose on Tuesday amid a large acquisition and data disregarded as weather related.
*Forest Labs shares soar; Actavis agrees to buy company. NEW YORK, Feb 18- The S&P 500 and Nasdaq rose on Tuesday, following Wall Street's biggest weekly gain of the year, as merger activity increased confidence that there is value in the stock market even as the benchmark index nears a record high.
*Forest Labs shares jump, Actavis to purchase. NEW YORK, Feb 18- U.S. stocks edged up on Tuesday, following Wall Street's biggest gain of the year, as merger activity boosted confidence there is still value in the market even as the S&P 500 nears a record high.
*Forest Labs surges after Actavis confirms acquisition. "Much of the recent concern over the health of the U.S. economy has been explained at the hands of the weather," said Andrew Wilkinson, chief market analyst at Interactive Brokers LLC in Greenwich, Connecticut.
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
*Forest Labs surges after Actavis confirms acquisition. NEW YORK, Feb 18- U.S. stocks were little changed on Tuesday after Wall Street's biggest gain of the year as disappointing economic reports weighed on investor sentiment.
Feb 18- Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, expanding its portfolio of specialty pharmaceuticals for neurological and other disorders. Actavis said it would pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest's closing price on Friday.
*Forest Labs surges after Actavis confirms acquisition. *Shares of Forest Laboratories Inc rocketed more than 35 percent in premarket trading after Actavis said it would acquire the specialty pharmaceuticals company in a massive cash and stock deal valued at about $25 billion.